2.11 USD
▼+0.08-2.76%
盘后 2.14 -1.38%
2026-08-03
市值
$33.91M
市盈率
0.01
EPS
382.20
股息率
—
52 周区间
1.80 – 31.50
成交量
467.43K
Beta
1.47
目标价
—
52W 低 1.8052W 高 31.50
价格走势
公司简介
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was forme...